tert -Butoxycarbonyl-Modification Driven Disturbance of Molecular Ordering Enables High-Efficiency Dual Drugs Co-Assembly for Synergistic Tumor Inhibition
ACS Nano · 2025
DOI: 10.1021/acsnano.4c16986 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Xuequan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, People's Republic of Ch…. Hauptthemen laut MEDLINE: Paclitaxel, Camptothecin, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Specific Research Project of Guangxi for Research Bases and Talents, Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
The development of carrier-free drug delivery systems (CDDS) for tailored drug combinations posed a significant challenge, particularly in achieving efficient co-assembly while maintaining therapeutic efficacy. Herein, we proposed a co-assembly strategy based on molecular engineering. Paclitaxel (PTX) and 7-ethyl-10-hydroxycamptothecin (SN38) were chemically modified with tert-butoxycarbonyl (BOC) groups. The successful incorporation of the BOC groups was confirmed by proton nuclear magnetic resonance and mass spectrometry analyses. Further characterization using polarized light microscopy and X-ray diffraction revealed that this modification significantly reduced the crystallinity of both drugs, while simultaneously disrupting their original ordered stacking structure. Molecular dynamics simulations indicated that BOC modification increased molecular spacing, reduced stacking density, and expanded molecular volume, resulting in a looser molecular packing arrangement. This structural alteration enabled the modified drug molecules to efficiently coassemble with α-tocopherol succinate (α-TOS) into spherical nanoparticles at a nearly predefined mass ratio. The resulting nanoparticles exhibited a high drug loading capacity of 52.66% and remained stable at 4 °C for over 50 days. Notably, these nanoparticles displayed controllable release characteristics at pH 5.0. Both in vitro and in vivo studies demonstrated the BOC-modified drugs retained their bioactivity. When co-assembled with α-TOS, the nanoparticles exhibited a significant synergistic antitumor effect and suppressed tumor metastasis through downregulation of matrix metalloproteinase-9 (MMP-9) expression. This study provided a solid theoretical foundation and innovative approach for the development of CDDS, utilizing molecular-scale regulation for drug co-assembly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, People's Republic of China.
Förderung
- Specific Research Project of Guangxi for Research Bases and Talents
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Zhang, X., Zhu, J., Li, T., Yang, L., Lei, L., Wu, F., He, B., & Cao, J. (2025). tert -Butoxycarbonyl-Modification Driven Disturbance of Molecular Ordering Enables High-Efficiency Dual Drugs Co-Assembly for Synergistic Tumor Inhibition. ACS Nano. https://doi.org/10.1021/acsnano.4c16986
Vancouver
Zhang X, Zhang X, Zhu J, Li T, Yang L, Lei L, et al. tert -Butoxycarbonyl-Modification Driven Disturbance of Molecular Ordering Enables High-Efficiency Dual Drugs Co-Assembly for Synergistic Tumor Inhibition. ACS Nano. 2025. doi:10.1021/acsnano.4c16986
BibTeX
@article{Zhang2025,
author = {Zhang, Xuequan and Zhang, Xiaoxian and Zhu, Jiahui and Li, Tinghua and Yang, Lianyi and Lei, Lei and Wu, Fang and He, Bin and Cao, Jun},
title = {tert -Butoxycarbonyl-Modification Driven Disturbance of Molecular Ordering Enables High-Efficiency Dual Drugs Co-Assembly for Synergistic Tumor Inhibition},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.4c16986}
}
EUVIMED